Form 4: Apellis Pharmaceuticals CSO Granted Significant Stock Options

Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, was granted 82,500 stock options with a $19.39 exercise price, vesting over two years.

Summary

• Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 82,500 stock options.
• The stock options have an exercise price of $19.39 per share.
• The grant date for these options was June 9, 2025.
• The options will vest over a two-year period, with 50% vesting on the one-year anniversary and the remaining 50% on the two-year anniversary of the grant date.
• Vesting is contingent upon Mr. Deschatelets' continued service with the company.
• The stock options have an expiration date of June 9, 2035.

Sentiment

Score: 7

Explanation: The document reports a standard executive compensation event (stock option grant). While not directly impacting operational results, it signifies continued executive alignment with company performance and retention, which is generally positive for corporate governance and stability.

Positives

• The grant of stock options to the Chief Scientific Officer aligns executive incentives with long-term shareholder value creation.
• The vesting schedule encourages continued service from a key executive, which can contribute to stability and continuity in leadership.

Future Outlook

The stock option grant, with its two-year vesting schedule, indicates an expectation of continued service from the Chief Scientific Officer, aligning his long-term interests with the company's future performance.

Management Comments

• The filing indicates a transaction made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

The granting of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, serving as a significant component of executive compensation packages designed to attract, retain, and motivate talent by aligning their financial interests with the company's long-term success and shareholder value.

Comparison to Industry Standards

• The structure of this stock option grant, including the exercise price and multi-year vesting schedule, is consistent with typical executive compensation practices observed across the biotechnology and pharmaceutical sectors.
• Companies like Biogen Inc. (BIIB) or Vertex Pharmaceuticals Inc. (VRTX) frequently utilize similar equity-based incentives to compensate their senior leadership, linking performance to stock price appreciation over time.

Corporate Governance

Related Party Transactions

• The stock option grant is a transaction between the company and an insider (Chief Scientific Officer), which is a common form of executive compensation.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the Chief Scientific Officer's financial interests with those of shareholders, potentially leading to more focused efforts on increasing stock value.
• Employees: While specific to one executive, such compensation practices can signal the company's commitment to retaining key talent, which can positively influence overall employee morale and stability.

Next Steps

• 50% of the granted stock options will vest on June 9, 2026, contingent on continued service.
• The remaining 50% of the granted stock options will vest on June 9, 2027, contingent on continued service.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Stock Options, Executive Compensation, Form 4, Pascal Deschatelets, Chief Scientific Officer, Equity Grant, Vesting